Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

Massimo Andreoni; Elisabetta Teti; Andrea Antinori; Laura Milazzoi; Savatore Sollima; Giuliano Rizzardini; Antonio Di Biagio; Annalisa Saracino; Raffaele Bruno; Vanni Borghi; Andrea De Luca; Annamaria Cattelan; Hamid Hasson; Gloria Taliani; Antonella D.Arminio Monforte; Claudio Maria Mastroianni; Giovanni Di Perri; Sara Bigoni; Massimo Puoti; Angiola Spinetti; Andrea Gori; Nicola Boffa; Bruno Cacopardo; Andrea Giacometti; Giustino Parruti; Vincenzo Vullo; Antonio Chirianni; Alfredo Pennica; Caterina Pasquazzi; Daniela Segala; Loredana Sarmati

doi:10.1093/cid/ciw846

Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

Massimo Andreoni, Elisabetta Teti, Andrea Antinori, Laura Milazzoi, Savatore Sollima, Giuliano Rizzardini, Antonio Di Biagio, Annalisa Saracino, Raffaele Bruno, Vanni Borghi, Andrea De Luca, Annamaria Cattelan, Hamid Hasson, Gloria Taliani, Antonella D.Arminio Monforte, Claudio Maria Mastroianni, Giovanni Di Perri, Sara Bigoni, Massimo Puoti, Angiola SpinettiAndrea Gori, Nicola Boffa, Bruno Cacopardo, Andrea Giacometti, Giustino Parruti, Vincenzo Vullo, Antonio Chirianni, Alfredo Pennica, Caterina Pasquazzi, Daniela Segala, Loredana Sarmati

Research output: Contribution to journal › Article › peer-review

Abstract

Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

Original language	English
Pages (from-to)	680-683
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	64
Issue number	5
DOIs	https://doi.org/10.1093/cid/ciw846
Publication status	Published - Jan 1 2017

Keywords

Anti-HCV therapy
Antiviral therapy
DAA
HIV/HCV coinfection
IFN-free

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciw846

Cite this

Andreoni, M., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., Di Biagio, A., Saracino, A., Bruno, R., Borghi, V., De Luca, A., Cattelan, A., Hasson, H., Taliani, G., Monforte, A. D. A., Mastroianni, C. M., Di Perri, G., Bigoni, S., Puoti, M., ... Sarmati, L. (2017). Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program. Clinical Infectious Diseases, 64(5), 680-683. https://doi.org/10.1093/cid/ciw846

Andreoni, M, Teti, E, Antinori, A, Milazzoi, L, Sollima, S, Rizzardini, G, Di Biagio, A, Saracino, A, Bruno, R, Borghi, V, De Luca, A, Cattelan, A, Hasson, H, Taliani, G, Monforte, ADA, Mastroianni, CM, Di Perri, G, Bigoni, S, Puoti, M, Spinetti, A, Gori, A, Boffa, N, Cacopardo, B, Giacometti, A, Parruti, G, Vullo, V, Chirianni, A, Pennica, A, Pasquazzi, C, Segala, D & Sarmati, L 2017, 'Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program', Clinical Infectious Diseases, vol. 64, no. 5, pp. 680-683. https://doi.org/10.1093/cid/ciw846

@article{cac3f81e1db245b3a5b4b9a67fd9f1ff,

title = "Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program",

abstract = "Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).",

keywords = "Anti-HCV therapy, Antiviral therapy, DAA, HIV/HCV coinfection, IFN-free",

author = "Massimo Andreoni and Elisabetta Teti and Andrea Antinori and Laura Milazzoi and Savatore Sollima and Giuliano Rizzardini and {Di Biagio}, Antonio and Annalisa Saracino and Raffaele Bruno and Vanni Borghi and {De Luca}, Andrea and Annamaria Cattelan and Hamid Hasson and Gloria Taliani and Monforte, {Antonella D.Arminio} and Mastroianni, {Claudio Maria} and {Di Perri}, Giovanni and Sara Bigoni and Massimo Puoti and Angiola Spinetti and Andrea Gori and Nicola Boffa and Bruno Cacopardo and Andrea Giacometti and Giustino Parruti and Vincenzo Vullo and Antonio Chirianni and Alfredo Pennica and Caterina Pasquazzi and Daniela Segala and Loredana Sarmati",

year = "2017",

month = jan,

day = "1",

doi = "10.1093/cid/ciw846",

language = "English",

volume = "64",

pages = "680--683",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection

T2 - Results of an Italian compassionate use program

AU - Andreoni, Massimo

AU - Teti, Elisabetta

AU - Antinori, Andrea

AU - Milazzoi, Laura

AU - Sollima, Savatore

AU - Rizzardini, Giuliano

AU - Di Biagio, Antonio

AU - Saracino, Annalisa

AU - Bruno, Raffaele

AU - Borghi, Vanni

AU - De Luca, Andrea

AU - Cattelan, Annamaria

AU - Hasson, Hamid

AU - Taliani, Gloria

AU - Monforte, Antonella D.Arminio

AU - Mastroianni, Claudio Maria

AU - Di Perri, Giovanni

AU - Bigoni, Sara

AU - Puoti, Massimo

AU - Spinetti, Angiola

AU - Gori, Andrea

AU - Boffa, Nicola

AU - Cacopardo, Bruno

AU - Giacometti, Andrea

AU - Parruti, Giustino

AU - Vullo, Vincenzo

AU - Chirianni, Antonio

AU - Pennica, Alfredo

AU - Pasquazzi, Caterina

AU - Segala, Daniela

AU - Sarmati, Loredana

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

AB - Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

KW - Anti-HCV therapy

KW - Antiviral therapy

KW - DAA

KW - HIV/HCV coinfection

KW - IFN-free

UR - http://www.scopus.com/inward/record.url?scp=85018188522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018188522&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw846

DO - 10.1093/cid/ciw846

M3 - Article

VL - 64

SP - 680

EP - 683

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -

Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this